Titration schedules, half-life, and route of administration — documented by the trials

The short version

Tirzepatide is given as a once-weekly injection under the skin. The FDA-approved prescribing label describes starting at 2.5 mg and increasing the dose every four weeks until reaching the target maintenance dose. The three maintenance doses studied in the large trials are 5 mg, 10 mg, and 15 mg per week. The drug stays in the body for about 5 days on average — that is why once-weekly dosing works. All of this is from the published label and clinical-trial protocols; it describes what was administered in trials, not a recommendation for any individual.

Tirzepatide dosage: the FDA-labeled titration schedule

The approved prescribing label documents a stepwise escalation schedule for tirzepatide. Initiation is at 2.5 mg once weekly for four weeks, titrated in 2.5 mg increments every four weeks to a maintenance dose of 5 mg once weekly, then optionally to 10 mg and 15 mg once weekly, the maximum studied in the phase 3 trials ^[9]. The titration is designed to improve gastrointestinal tolerability; nausea and vomiting are most frequent during the first weeks at each new dose level and generally attenuate with continued exposure.

The three maintenance doses studied in the SURPASS and SURMOUNT phase 3 programmes are 5 mg, 10 mg, and 15 mg once weekly — these are the labelled therapeutic dose range. In SURMOUNT-5, the protocol specified escalation to the maximum tolerated dose (10 or 15 mg) for each participant ^[8].

Tirzepatide dose response is consistent across both the HbA1c and weight outcomes: SURPASS-2 HbA1c reductions were 2.01, 2.24, and 2.30 percentage points at 5, 10, and 15 mg respectively ^[1]; SURMOUNT-1 weight changes were -15.0%, -19.5%, and -20.9% at the same doses ^[6].

Tirzepatide dose: pharmacokinetics and half-life

The approximately 5-day elimination half-life results directly from the molecular engineering: a C20 fatty diacid side chain attached via a glutamic-acid linker and two short spacers to a lysine residue on the 39-amino-acid GIP backbone drives high-affinity albumin binding in the bloodstream, slowing clearance and producing the long half-life that supports once-weekly dosing ^[5]. Steady-state plasma concentrations are reached after approximately 4 weeks of once-weekly dosing.

Route studied: subcutaneous injection only. The approved and trial programme uses a subcutaneous (under the skin) solution. No oral or intravenous formulation is part of the approved or active investigational programme for the indications described on this site.

Recommended injection sites per the prescribing label include the abdomen, thigh, and upper arm; the site is rotated at each administration.

Tirzepatide injection: stability and formulation notes

Tirzepatide injection in the approved formulation is refrigerated. The specific storage and handling parameters are documented in the prescribing label and product packaging for the approved formulation and are outside the scope of the efficacy literature reviewed on this site. Clinical-trial product is a subcutaneous solution; trial protocols describe the stepwise escalation schedules documented above.

The safety profile is dose-related. A meta-analysis of nine randomised trials found that gastrointestinal adverse events are more frequent at higher doses and during dose escalation ^[6]. Discontinuation due to adverse events was approximately 32% higher with tirzepatide versus an established comparator in a meta-analysis of three head-to-head trials ^[4].

Tirzepatide side effects: frequency and onset

Across the phase 3 trial programmes, gastrointestinal adverse events are the dominant safety signal. In SURMOUNT-1 (n=2,539), the most common adverse events with tirzepatide were: nausea (up to 31.0%), diarrhoea (up to 22.1%), vomiting (up to 12.3%), and constipation (up to 17.8%) across dose groups, occurring most frequently during dose escalation and generally mild to moderate in severity ^[6].

A post-hoc analysis of SURPASS participants confirmed that weight loss in the trials occurred independently of whether gastrointestinal adverse events were experienced, meaning the weight effect is not simply a consequence of reduced food intake from nausea ^[13].

Specific safety signals with supporting evidence from the trials:

• Gallbladder and biliary disease: composite RR 1.97 (95% CI 1.14-3.42) across nine trials (n=9,871) ^[6]
• Pancreatitis: RR 1.46 (95% CI 0.59-3.61) — not statistically significant in the meta-analysis ^[6]
• Lean-mass loss: approximately 25% of weight lost as lean mass in SURMOUNT-1 DXA substudy ^[2]
• Thyroid C-cell tumours: rodent-derived label warning, not confirmed in humans ^[9]

The full community-reported side-effect profile — including injection-site reactions, hair thinning, taste changes, and sulfur burps — is on the effects page.